IL195667A0 - A conjugate of an antibody against ccr5 and an antifusogenic peptide - Google Patents
A conjugate of an antibody against ccr5 and an antifusogenic peptideInfo
- Publication number
- IL195667A0 IL195667A0 IL195667A IL19566708A IL195667A0 IL 195667 A0 IL195667 A0 IL 195667A0 IL 195667 A IL195667 A IL 195667A IL 19566708 A IL19566708 A IL 19566708A IL 195667 A0 IL195667 A0 IL 195667A0
- Authority
- IL
- Israel
- Prior art keywords
- conjugate
- antibody against
- antifusogenic peptide
- against ccr5
- ccr5
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06017156 | 2006-08-17 | ||
EP06020647 | 2006-09-29 | ||
EP07014335 | 2007-07-20 | ||
PCT/EP2007/007164 WO2008019817A1 (en) | 2006-08-17 | 2007-08-14 | A conjugate of an antibody against ccr5 and an antifusogenic peptide |
Publications (1)
Publication Number | Publication Date |
---|---|
IL195667A0 true IL195667A0 (en) | 2009-09-01 |
Family
ID=38877282
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL195667A IL195667A0 (en) | 2006-08-17 | 2008-12-02 | A conjugate of an antibody against ccr5 and an antifusogenic peptide |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP2054086A1 (en) |
JP (1) | JP2010500984A (en) |
KR (1) | KR101105610B1 (en) |
AU (1) | AU2007286451A1 (en) |
BR (1) | BRPI0715794A2 (en) |
CA (1) | CA2658474A1 (en) |
IL (1) | IL195667A0 (en) |
MX (1) | MX2009001204A (en) |
WO (1) | WO2008019817A1 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130195881A1 (en) * | 2007-04-27 | 2013-08-01 | Sanjaya Singh | Potent, stable and non-immunosuppressive anti-cd4 antibodies |
AR067584A1 (en) * | 2007-07-20 | 2009-10-14 | Hoffmann La Roche | A CONJUGATE OF AN ANTIBODY AGAINST CD4 AND ANTIFUSOGENIC PEPTIDES |
WO2009155064A1 (en) * | 2008-05-28 | 2009-12-23 | New York Blood Center | Bifunctional molecules for inhibiting hiv entry |
WO2010028796A1 (en) * | 2008-09-10 | 2010-03-18 | F. Hoffmann-La Roche Ag | Trispecific hexavalent antibodies |
CA2739288A1 (en) | 2008-10-16 | 2010-04-22 | Shibo Jiang | Immunoenhancer-linked oligomeric hiv vaccines |
CA2751865A1 (en) | 2009-02-09 | 2010-08-12 | New York Blood Center, Inc. | Trimeric hiv fusion inhibitors for treating or preventing hiv infection |
EP2566493B1 (en) | 2010-05-03 | 2015-03-04 | New York Blood Center, Inc. | Bifunctional molecules for inactivating hiv and blocking hiv |
CA2916202C (en) | 2013-06-24 | 2019-07-02 | Hanwha Chemical Corporation | Antibody-drug conjugate having improved stability and use thereof |
HUE059788T2 (en) | 2015-10-02 | 2022-12-28 | Symphogen As | Anti-pd-1 antibodies and compositions |
US12030942B2 (en) | 2015-10-02 | 2024-07-09 | Les Laboratoires Servier | Anti-PD-1 antibodies and compositions |
EP3541841B1 (en) | 2016-11-18 | 2024-09-11 | Les Laboratoires Servier | Anti-pd-1 antibodies and compositions |
CA3185303A1 (en) | 2017-04-05 | 2018-10-11 | Symphogen A/S | Combination therapies targeting pd-a, tim-3, and lag-3 |
JP2020519309A (en) * | 2017-05-10 | 2020-07-02 | アルバジュナ・セラピューティクス・エセ・エレ | Fc fusion protein derivatives with high dual HIV antiviral and immunomodulatory activity |
JP2022516408A (en) * | 2018-12-14 | 2022-02-28 | インセルム(インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル) | Isolated MHC-derived human peptides and their use for stimulating and activating the inhibitory function of CD8 + CD45RCrowTreg. |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
FR2654429B1 (en) | 1989-11-13 | 1992-03-06 | Panmedica Sa | NOVEL 3,3,5-TRIMETHYLCYCLOHEXANOL METHYL-2-PROPIONATE DERIVATIVES, THEIR PREPARATION PROCESS AND THE THERAPEUTIC COMPOSITIONS CONTAINING THEM. |
AU662891B2 (en) * | 1990-11-27 | 1995-09-21 | Biogen Idec Ma Inc. | Anti CD-4 antibodies blocking HIV-induced syncytia |
NZ254640A (en) | 1992-07-20 | 1997-04-24 | Univ Duke | Hiv protein fragments of transmembrane glycoprotein gp41 (dp-107) with antiviral activity and their use |
US6479055B1 (en) | 1993-06-07 | 2002-11-12 | Trimeris, Inc. | Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission |
US5464933A (en) | 1993-06-07 | 1995-11-07 | Duke University | Synthetic peptide inhibitors of HIV transmission |
US6017536A (en) | 1993-06-07 | 2000-01-25 | Trimeris, Inc. | Simian immunodeficiency virus peptides with antifusogenic and antiviral activities |
US6743594B1 (en) | 1995-06-06 | 2004-06-01 | Human Genome Sciences, Inc. | Methods of screening using human G-protein chemokine receptor HDGNR10 (CCR5) |
AU723537B2 (en) | 1995-06-07 | 2000-08-31 | Trimeris Inc. | The treatment of HIV and other viral infections using combinatorial therapy |
EP0975749A2 (en) | 1996-05-28 | 2000-02-02 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Cc chemokine receptor 5, antibodies thereto, transgenic animals |
US6528625B1 (en) | 1996-10-28 | 2003-03-04 | Millennium Pharmaceuticals, Inc. | Anti-CCR5 antibodies and kits comprising same |
WO1998033523A1 (en) | 1997-01-31 | 1998-08-06 | Biovation Limited | Vaccination methods and molecules |
DE69833755T2 (en) | 1997-05-21 | 2006-12-28 | Biovation Ltd. | METHOD FOR PRODUCING NON-IMMUNOGENOUS PROTEINS |
US6656906B1 (en) | 1998-05-20 | 2003-12-02 | Trimeris, Inc. | Hybrid polypeptides with enhanced pharmacokinetic properties |
US6258782B1 (en) | 1998-05-20 | 2001-07-10 | Trimeris, Inc. | Hybrid polypeptides with enhanced pharmacokinetic properties |
AU4891899A (en) | 1998-07-22 | 2000-02-14 | Osprey Pharmaceuticals Limited | Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders |
US20030215421A1 (en) | 1999-07-21 | 2003-11-20 | Mcdonald John R. | Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders |
US20030099645A1 (en) | 2000-10-10 | 2003-05-29 | Lobo Peter Isaac | Naturally occuring IgM antibodies that bind to membrane receptors on lymphocytes |
US6610834B1 (en) | 1998-11-18 | 2003-08-26 | Peter I. Lobo | Human IgM antibodies to chemokine receptors |
EP1051432B1 (en) | 1998-12-08 | 2007-01-24 | Biovation Limited | Method for reducing immunogenicity of proteins |
DE69937369T2 (en) | 1998-12-16 | 2008-07-24 | Progenics Pharmaceuticals, Inc. | CCR5 antibody PA14 |
WO2000053633A2 (en) | 1999-03-11 | 2000-09-14 | Micromet Ag | Antibody and chemokine constructs that are directed to ccr5, and their use for treating autoimmune diseases |
JP4216480B2 (en) | 1999-05-17 | 2009-01-28 | コンジュケム バイオテクノロジーズ インコーポレイテッド | Long-lasting fusion peptide inhibitors of viral infection |
US20030049251A1 (en) | 1999-12-08 | 2003-03-13 | Barbas Carlos F. | Methods and compositions useful for inhibiting ccr5-dependent infection of cells by hiv-1 |
AU2265701A (en) | 1999-12-16 | 2001-06-25 | Tanox, Inc. | Anti-hiv-1 conjugates for treatment of hiv disease |
KR20030032916A (en) | 2000-02-09 | 2003-04-26 | 휴먼 게놈 사이언시즈, 인크. | Antibodies to ccr5 |
US20040043033A1 (en) | 2000-05-01 | 2004-03-04 | Green Lorrence H. | Method and vaccine for the prevention of AIDS |
US7138119B2 (en) | 2000-09-15 | 2006-11-21 | Progenics Pharmaceuticals, Inc. | Compositions and methods for inhibition of HIV-1 infection |
US20030165988A1 (en) | 2002-02-08 | 2003-09-04 | Shaobing Hua | High throughput generation of human monoclonal antibody against peptide fragments derived from membrane proteins |
US7005503B2 (en) | 2002-02-08 | 2006-02-28 | Genetastix Corporation | Human monoclonal antibody against coreceptors for human immunodeficiency virus |
EP1207202A1 (en) | 2000-11-16 | 2002-05-22 | Mölling, Karin, Inst. für med. Virologie der Uni. Zürich | Nucleic acid molecules encoding a protein interacting with the chemokine receptor CCR5 or other chemokine receptor family members |
US20020147147A1 (en) | 2000-11-16 | 2002-10-10 | Karin Molling | Nucleic acid molecules encoding a protein interacting with the chemokine receptor CCR5 or other chemokine receptor family members |
US7175988B2 (en) | 2001-02-09 | 2007-02-13 | Human Genome Sciences, Inc. | Human G-protein Chemokine Receptor (CCR5) HDGNR10 |
US20030003440A1 (en) | 2001-03-14 | 2003-01-02 | Lucia Lopalco | Novel CCR5 epitope and antibodies against it |
US20020146415A1 (en) | 2001-04-06 | 2002-10-10 | Olson William C. | Methods for inhibiting HIV-1 infection |
US7060273B2 (en) | 2001-04-06 | 2006-06-13 | Progenics Pharmaceuticals, Inc. | Methods for inhibiting HIV-1 infection |
US7223844B2 (en) | 2001-10-16 | 2007-05-29 | United States Of America, Represented By The Secretary, Department Of Health And Human Services | Broadly cross-reactive neutralizing antibodies against human immunodeficiency virus selected by Env-CD4-co-receptor complexes |
AU2003209059A1 (en) | 2002-02-08 | 2003-09-02 | Genetastix Corporation | Human monoclonal antibodies against membrane proteins |
CN1780907B (en) | 2002-02-22 | 2011-06-15 | 原基因药物有限公司 | Anti-CCR5 antibody |
US7122185B2 (en) | 2002-02-22 | 2006-10-17 | Progenics Pharmaceuticals, Inc. | Anti-CCR5 antibody |
JP2006503849A (en) * | 2002-09-27 | 2006-02-02 | タノックス インコーポレーテッド | Synergistic composition for prevention and treatment of acquired immune deficiency syndrome |
TWI353991B (en) * | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
US20050281829A1 (en) | 2003-05-06 | 2005-12-22 | Hehir Cristina A T | Fc chimeric proteins with anti-HIV drugs |
WO2004103312A2 (en) * | 2003-05-19 | 2004-12-02 | Progenics Pharmaceuticals, Inc. | Peptides useful as hiv fusion inhibitors |
JP2007517522A (en) | 2004-01-07 | 2007-07-05 | トリメリス,インコーポレーテッド | Synthetic peptides derived from HIV gp41HR2 and their use in therapy to prevent the spread of human immunodeficiency virus |
US7551647B2 (en) * | 2004-07-19 | 2009-06-23 | Qvidium Technologies, Inc. | System and method for clock synchronization over packet-switched networks |
-
2007
- 2007-08-14 MX MX2009001204A patent/MX2009001204A/en active IP Right Grant
- 2007-08-14 EP EP07801642A patent/EP2054086A1/en not_active Withdrawn
- 2007-08-14 KR KR1020097003147A patent/KR101105610B1/en not_active IP Right Cessation
- 2007-08-14 WO PCT/EP2007/007164 patent/WO2008019817A1/en active Application Filing
- 2007-08-14 AU AU2007286451A patent/AU2007286451A1/en not_active Abandoned
- 2007-08-14 JP JP2009524111A patent/JP2010500984A/en not_active Ceased
- 2007-08-14 BR BRPI0715794-0A patent/BRPI0715794A2/en not_active IP Right Cessation
- 2007-08-14 CA CA002658474A patent/CA2658474A1/en not_active Abandoned
-
2008
- 2008-12-02 IL IL195667A patent/IL195667A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2010500984A (en) | 2010-01-14 |
AU2007286451A1 (en) | 2008-02-21 |
EP2054086A1 (en) | 2009-05-06 |
BRPI0715794A2 (en) | 2013-07-23 |
KR20090037944A (en) | 2009-04-16 |
CA2658474A1 (en) | 2008-02-21 |
KR101105610B1 (en) | 2012-01-18 |
WO2008019817A1 (en) | 2008-02-21 |
MX2009001204A (en) | 2009-02-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL195667A0 (en) | A conjugate of an antibody against ccr5 and an antifusogenic peptide | |
IL202565A0 (en) | A conjugate of an antibody against cd4 and antifusogenic peptides | |
EP2097091A4 (en) | Conjugate of natriuretic peptide and antibody constant region | |
IL186071A0 (en) | Antibodies against ccr5 and uses thereof | |
DK2064239T3 (en) | Anti-activin a antibodies and uses thereof | |
IL240245A (en) | Anti-5t4 antibodies and uses thereof | |
IL184565A0 (en) | Conjugates of a polypeptide and an oligosaccharide | |
IL196397A0 (en) | Prlr-specific antibody and uses thereof | |
ZA200810311B (en) | Anti-NKG2A antibodies and uses thereof | |
HK1143379A1 (en) | Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates tenb2 | |
IL196861A0 (en) | Antibodies against ccr5 and uses thereof | |
EP2111237A4 (en) | Fibrin-binding peptides and conjugates thereof | |
EP2170363A4 (en) | Tissue specific peptide conjugates and methods | |
GB0601102D0 (en) | Kinase Peptides And Antibodies | |
IL195839A0 (en) | New protein conjugates and methods for their preparation | |
IL195525A0 (en) | Replikin peptides and uses thereof | |
EP2077325A4 (en) | Monoclonal antibody and use thereof | |
GB0604187D0 (en) | Peptide and uses thereof | |
EP2004231A4 (en) | Conjugates of an anti-tnf-alpha antibody | |
EP1996938A4 (en) | Immobilized proteins and methods and uses thereof | |
EP2066696A4 (en) | Anti-cancer antibodies against lewisy and lewisb antigens | |
GB0617564D0 (en) | Peptides and methods | |
EP2020417A4 (en) | Prostasin partial peptide and anti-prostasin antibody | |
IL192800A0 (en) | Fgf2-binding peptides and uses thereof | |
AU2006903659A0 (en) | Antibodies and related methods |